All articles by Srivani Venna

Srivani Venna

Plus Therapeutics completes enrolment in second cohort of LM trial

The incidence and severity of adverse events/serious adverse events and dose limiting toxicities are the primary endpoints.

GreenLight receives Rwanda FDA approval for Covid-19 mRNA vaccine trial

The Phase I/II clinical trial will evaluate the safety and immunogenicity of the vaccine.

Mural Health, Ledger Run to collaborate for clinical operations improvement

The Mural Link platform offers payment technology that helps participants select the way they receive payments.

First Wave BioPharma to initiate trial of adrulipase for cystic fibrosis

Secondary endpoints of the trial include signs and symptoms of malabsorption, stool weight, and coefficient of nitrogen absorption.

Boehringer Ingelheim reports positive data from trial of spesolimab for GPP

The new humanised antibody spesolimab is currently indicated to treat GPP flares in adults.

AmMax Bio doses first subjects in Phase IIb trial of TGCT therapy

Initial data from the Phase IIb clinical trial is expected in the second half of this year.

Janssen’s trial of CARVYKTI for multiple myeloma meets primary endpoint

Janssen Biotech and Legend Biotech USA signed an agreement in December 2017 to develop and commercialise CARVYKTI.

HuidaGene receives FDA clearance for retinal dystrophies therapy trial

The trial aims to assess HG004’s tolerability, safety, efficacy, and long-term durability when given as a single injection.

Bristol Myers Squibb reports data from trial of Breyanzi for CLL

Data from the TRANSCEND CLL 004 trial showed that the study met the primary endpoint of complete response rate.

MHRA authorises Decibel’s CTA for trial of DB-OTO in paediatric patients

DB-OTO is being developed by Decibel, in partnership with Regeneron Pharmaceuticals.